Jiangsu Hengrui Medicine Valuation

Q: What is the Fair Price of 1276 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

1276 (HK$55.15) is trading below our estimate of [[fair value]] (HK$65.24)

Is 1276 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1276 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow

Simply Wall St

HK$65.24

Fair Value

15.5% undervalued

Number of Analysts

Below Fair Value: 1276 (HK$55.15) is trading below our estimate of fair value (HK$65.24)

Significantly Below Fair Value: 1276 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1276?

Key metric: As 1276 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1276. This is calculated by dividing 1276's market cap by their current earnings.
What is 1276's PE Ratio?
PE Ratio	52.8x
Earnings	CN¥6.84b
Market Cap	CN¥360.49b

1276 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	11.5x
Enterprise Value/EBITDA	43.5x
PEG Ratio	4.3x

Price to Earnings Ratio vs Peers

How does 1276's PE Ratio compare to its peers?

The above table shows the PE ratio for 1276 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	24.2x
3692 Hansoh Pharmaceutical Group	32x	7.99%	HK$152.5b
1093 CSPC Pharmaceutical Group	16x	4.89%	HK$75.7b
1177 Sino Biopharmaceutical	35.7x	16.54%	HK$74.8b
512 Grand Pharmaceutical Group	13x	3.25%	HK$32.2b
1276 Jiangsu Hengrui Medicine	52.8x	12.34%	HK$360.5b

Price-To-Earnings vs Peers: 1276 is expensive based on its Price-To-Earnings Ratio (52.8x) compared to the peer average (24.2x).

Price to Earnings Ratio vs Industry

How does 1276's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
858 Extrawell Pharmaceutical Holdings	0.7x	n/a	US$15.87m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 1276 is expensive based on its Price-To-Earnings Ratio (52.8x) compared to the Hong Kong Pharmaceuticals industry average (10.7x).

Price to Earnings Ratio vs Fair Ratio

What is 1276's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1276 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	52.8x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1276's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

AnalystConsensusTarget

Consensus Narrative from 15 Analysts

HK$64.02

Fair Value

13.9% undervalued

Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/25 08:55
End of Day Share Price	2025/05/23 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Jiangsu Hengrui Medicine Co., Ltd. is covered by 56 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ling Zhang	BNP Paribas Securities (Asia)
Changming He	BOCI Research Ltd.
Bo Li	BofA Global Research